AA-T3A-C12 is an anisamide ligand-tethered lipidoid (AA-lipidoid) with high potency and selectivity to deliver RNA payloads to activated fibroblasts. HSP47 siRNA (siHSP47)-loaded AA-T3A-C12 LNP achieves ~65% knockdown and dramatically reduces liver fibrosis, which significantly outperforms the benchmark DLin-MC3-DMA (MC3) LNP.

ALC-0315 analogue-2 is an analogue of ALC-0315. ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine.

Lipid 6 is an ionizable amino lipid used for the generation of Lipid nanoparticles .

A2-Iso5-4DC19 is a lipidoid compound. A2-Iso5-4DC19 is an effective carrier for the delivery of an agent such as a polynucleotide to a cell.

Lipid 15 is an ionizable amino lipid used for the generation of Lipid nanoparticles .

LNP Lipid-5 (Compound Lipid 2) is an ionizable lipid (amino lipid). LNP Lipid-5 can be used to prepare lipid nanoparticles .

R6 is a new ionizable lipid driven from AI-Guided Ionizable Lipid Engineering (AGILE) platform for mRNA delivery. R6 LNPs exhibits a 5-fold increase in transfection potency in RAW 264.7 and shows its potential to be utilized for the development of non-viral mRNA delivery vectors for immune cells.

H9 is a new ionizable lipid driven from AI-Guided Ionizable Lipid Engineering (AGILE) platform for mRNA delivery. H9 LNPs shows superior mRNA transfection potency compared to LNPs containing (D-Lin-MC3-DMA).

C12-TLRa is an adjuvant lipidoid. C12-TLRa substitution can enhance the immunogenicity of clinically relevant SARS-CoV-2 mRNA-LNP vaccines, which holds translational potential.

ALC-0315 analgous-3 is an butanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315.

BP Lipid 114 is an ethanolamine ionizable lipid with 9 carbon of primary-ester lipid tail. The ethanolamine head helps with mRNA encapsulation. The ester bonds are located at C6 and C8 position relative to the amine nitrogen. The introduction of ester linkages can improve the clearance of the lipid in the liver. Reagent grade, for research purpose.

Lipid 121 is an amino lipid which has a long (11 carbons) lipid tail on the primary ester located at C7 relative to nitrogen amine. The head contains ethanolamine which can efficiently encapsulate mRNA. The secondary ester is introduced, on the ester located at C8 position relative to amine, to improve protein expression in the liver. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile. Reagent grade, for research purpose.

C12-113 is a novel polyamine-derived lipidoid for gene delivery.

BP Lipid 135 is an amino ionizable lipid with propanolamine lipid head which can improve mRNA encapsulation. The ester bonds are located at C8 position relative to nitrogen amine. There is 9 carbons chain on the primary ester lipid tail. The lipid can be used for preparation mRNA vesicle in gene therapy. Reagent grade, for research purpose.

An analog of SM-102. The ethanolamine amino lipid head enhances encapsulation of mRNA. The lipid has primary esters at C7 position relative to the amine nitrogen. The primary lipid tail has 8 carbon tail. The lipid can be used for mRNA-based therapies which depends on the availability of a safe and efficient delivery vehicle.

LNP Lipid-2 is a lipid product can be used to deliver agents.

SM-102 Analog 2(Compound 8-8) is a lipid compound. SM-102 Analog 2(Compound 8-8) is involved in the synthesis of lipid nanoparticles compositions. SM-102 Analog 2(Compound 8-8) has potential applications in the transportation of biologically active substances.

LNP Lipid-6 (Compound Lipid 5) is an ionizable lipid (amino lipid). LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP).

Lipidoid XMaN6 is an ionizable lipid with universality was screened out from the adamantyl-based ionizable lipid series, which could functionally deliver highly diverse types of nucleic acids. Among them, the XMaN6 iLNPs were the best-delivering vectors. XMaN6 was used to deliver mRNA, siRNA, pDNA, and cyclic dinucleotide into different cells, including human primary hepatocytes, HEK293T, Huh7, HepG2, and U2OS cell, with nontoxicity after a single dose.The non-toxic XMaN6 lipidoid is highly versatile in entrapment and delivery of siRNA, mRNA, plasmid DNA, and a cyclic dinucleotide. XMaN6-based LNPs efficiently deliver: 1) siRNA into human primary hepatocytes and cell lines that are hard-to-transfect, 2) mRNA into mouse liver, 3) plasmid DNA, 4) 2′,3′-cGAMP into cells and activated the cGAS-STING pathway three orders of magnitude more efficiently than 2′,3′-cGAMP alone. To our knowledge, such universality in delivering different NA types has not been previously described and can accelerate translation of LNPs into the clinic.

ssPalmE-P4C2 contained vitamin E (α-tocopherol) as a hydrophobic scaffold instead of oleic acid. ssPalmE-P4C2 was reported to have the ability to deliver siRNA to the liver. LNPssPalmE-P4C2 and LNPssPalmO-P4C2 showed a comparable knockdown efficiency (15.4 ± 8.7% and 19.2 ± 4.4%, respectively).

Lipid 16 is a potent cell type-specific ionizable lipid for the CD11b/hi macrophage population.

Lipid 23 is an ionizable cationic amino lipid (pKa = 5.7) that has been used with other lipids in the formulation of lipid nanoparticles (LNPs). Intravenous administration of LNPs containing lipid 23 and encapsulating an mRNA reporter accumulate specifically in the mouse liver.